HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
TSX-V:HITI - TSX Venture Exchange - CA42981E4013 - Common Stock - Currency: CAD
We assign a fundamental rating of 4 out of 10 to HITI. HITI was compared to 32 industry peers in the Pharmaceuticals industry. While HITI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, HITI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year HITI has reported negative net income.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
Of the past 5 years HITI 4 years had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -2.89%, HITI is doing good in the industry, outperforming 62.50% of the companies in the same industry.
With a decent Return On Equity value of -4.77%, HITI is doing good in the industry, outperforming 65.63% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.61%, HITI belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.89% | ||
| ROE | -4.77% | ||
| ROIC | 4.61% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HITI's Operating Margin of 2.41% is fine compared to the rest of the industry. HITI outperforms 68.75% of its industry peers.
The Gross Margin of HITI (26.45%) is worse than 65.63% of its industry peers.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.41% | ||
| PM (TTM) | N/A | ||
| GM | 26.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HITI is destroying value.
Compared to 1 year ago, HITI has more shares outstanding
HITI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HITI has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.07 indicates that HITI is not in any danger for bankruptcy at the moment.
The Altman-Z score of HITI (3.07) is better than 84.38% of its industry peers.
The Debt to FCF ratio of HITI is 3.51, which is a good value as it means it would take HITI, 3.51 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HITI (3.51) is better than 84.38% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that HITI is not too dependend on debt financing.
HITI has a Debt to Equity ratio (0.40) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | 3.51 | ||
| Altman-Z | 3.07 |
ROIC/WACC0.56
WACC8.23%
2.3 Liquidity
A Current Ratio of 1.61 indicates that HITI should not have too much problems paying its short term obligations.
HITI has a Current ratio (1.61) which is in line with its industry peers.
HITI has a Quick Ratio of 1.61. This is a bad value and indicates that HITI is not financially healthy enough and could expect problems in meeting its short term obligations.
HITI has a Quick ratio (0.95) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased strongly by -830.00% in the last year.
Looking at the last year, HITI shows a very negative growth in Revenue. The Revenue has decreased by -12.84% in the last year.
Measured over the past years, HITI shows a very strong growth in Revenue. The Revenue has been growing by 75.59% on average per year.
EPS 1Y (TTM)-830%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-688.64%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%11.24%
3.2 Future
The Earnings Per Share is expected to grow by 74.44% on average over the next years. This is a very strong growth
HITI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.65% yearly.
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.65%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 60.71, which means the current valuation is very expensive for HITI.
HITI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HITI is cheaper than 78.13% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.42, HITI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 60.71 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HITI indicates a somewhat cheap valuation: HITI is cheaper than 78.13% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, HITI is valued a bit cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.97 | ||
| EV/EBITDA | 7.58 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HITI does not grow enough to justify the current Price/Earnings ratio.
HITI's earnings are expected to grow with 65.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.97%
EPS Next 3Y65.89%
5. Dividend
5.1 Amount
HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (5/6/2025, 7:00:00 PM)
3.27
+0.02 (+0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.23%
Inst Owner ChangeN/A
Ins Owners8.82%
Ins Owner ChangeN/A
Market Cap264.67M
Analysts80
Price Target6.97 (113.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-163.56%
Min EPS beat(2)-315.76%
Max EPS beat(2)-11.37%
EPS beat(4)2
Avg EPS beat(4)-25.59%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)6
Avg EPS beat(8)36.42%
EPS beat(12)9
Avg EPS beat(12)22.45%
EPS beat(16)12
Avg EPS beat(16)20.89%
Revenue beat(2)2
Avg Revenue beat(2)1.38%
Min Revenue beat(2)1.15%
Max Revenue beat(2)1.6%
Revenue beat(4)3
Avg Revenue beat(4)0.28%
Min Revenue beat(4)-3.51%
Max Revenue beat(4)1.9%
Revenue beat(8)6
Avg Revenue beat(8)0.63%
Revenue beat(12)10
Avg Revenue beat(12)9.67%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)0%
PT rev (3m)11.56%
EPS NQ rev (1m)-83.35%
EPS NQ rev (3m)-466.7%
EPS NY rev (1m)-69.23%
EPS NY rev (3m)-375%
Revenue NQ rev (1m)-5.07%
Revenue NQ rev (3m)-2.46%
Revenue NY rev (1m)-2.41%
Revenue NY rev (3m)-1.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 60.71 | ||
| P/S | 0.49 | ||
| P/FCF | 13.97 | ||
| P/OCF | 9.02 | ||
| P/B | 1.85 | ||
| P/tB | 5.26 | ||
| EV/EBITDA | 7.58 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.05
Fwd EY1.65%
FCF(TTM)0.23
FCFY7.16%
OCF(TTM)0.36
OCFY11.09%
SpS6.63
BVpS1.76
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.89% | ||
| ROE | -4.77% | ||
| ROCE | 6.81% | ||
| ROIC | 4.61% | ||
| ROICexc | 5.54% | ||
| ROICexgc | 12.35% | ||
| OM | 2.41% | ||
| PM (TTM) | N/A | ||
| GM | 26.45% | ||
| FCFM | 3.53% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score4
Asset Turnover2.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | 3.51 | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 42.69% | ||
| Cap/Sales | 1.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 78.67% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | 3.07 |
F-Score4
WACC8.23%
ROIC/WACC0.56
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-830%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-688.64%
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%11.24%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.65%
EBIT growth 1Y903.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.17%
EBIT Next 3Y105.72%
EBIT Next 5Y67.86%
FCF growth 1Y28370.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y258.25%
OCF growth 3YN/A
OCF growth 5YN/A